PDE10A is a regulatory protein involved in the signaling of the striatum, a region of the brain important for controlling movement and cognition. Dysfunction of the striatum has been linked to the development of schizophrenia.

A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s). The ubiquitous presence of this ...

Jun 26, 2023 · Phosphodiesterase inhibitors are class medications used in the management and treatment of chronic obstructive pulmonary disease (COPD), erectile dysfunction (ED), pulmonary arterial hypertension (PAH), benign prostatic hyperplasia (BPH), acute decompensated heart failure, psoriasis, psoriatic arthritis (PA), atopic dermatitis (AD), and neonatal...

PDE10A is a dual cAMP/cGMP hydrolyzing enzyme which has triggered considerable interest over the last few years thanks to its high expression in the brain and in particular in the striatal medium spiny neurons in conjunction with its relatively low expression in periphery.

PBF-999, a dual adenosine A2a receptor antagonist/PDE 10 inhibitor, is investigated in a Phase 1 Recruiting trial (NCT03786484) in patients with immunotherapy-naïve and pretreated advanced solid tumors.

Inhibition of PDE10A represents a molecular target in the treatment of conditions that would benefit from the increase of the level of cAMP and/or cGMP such as neurological and psychiatric disorders, cancer, and diabetes.

Phosphodiesterase type 10 (PDE10) is a type of phosphodiesterase enzyme. Some inhibitors include papaverine, PF-2545920, TC-E 5005, and tofisopam.

Inhibitors of PDE10 (PDE10-Is) are a conceptually rational subject for medicinal chemistry with potential use in the treatment of psychiatric and neurodegenerative diseases.

Mar 30, 2025 · PDE10A (Phosphodiesterase 10A) is a Protein Coding gene. Diseases associated with PDE10A include Dyskinesia, Limb And Orofacial, Infantile-Onset and Striatal Degeneration, Autosomal Dominant 2. Among its related pathways are GPCR downstream signalling and Nitric oxide stimulates guanylate cyclase.

PDE10A, a phosphodiesterase that inactivates both cAMP and cGMP, is a unique signaling molecule in being highly and nearly exclusively expressed in striatal medium spiny neurons. These neurons dynamically integrate cortical information with dopamine-signaled value to mediate action selection among available behavioral options.